

NEWS 9 MAY 30 USPATFULL/USPAT2
NEWS 10 JUN 02 The F-Term thesaurus is now available in CA/CAplus
NEWS 11 JUN 26 The first reclassification of IPC codes now complete in
INPADOC
NEWS 12 JUN 28 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS EXPRESS Price changes in full-text patent databases EPFULL and PCTFULL
NEWS HOURS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>
NEWS LOGIN STN Operating Hours Plus Help Desk Availability
NEWS IPC8 Welcome Banner and News Items
NEWS X25 For general information regarding STN implementation of IPC 8
X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:08:06 ON 29 JUN 2006

FILE 'PCTFULL' ENTERED AT 13:08:26 ON 29 JUN 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 27 JUN 2006 <20060627/UP>
MOST RECENT UPDATE WEEK: 200625 <200625/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
SEE
<http://www.stn-international.de/stndatabases/details/IPC-RE>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<

>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,
PLEASE SEE HELP COST <<<

```
=> s MDH or (mitochondrial malate dehydrogenase)
    789 MDH
    9 MDHS
    794 MDH
          (MDH OR MDHS)
10031 MITOCHONDRIAL
    1 MITOCHONDRIALS
10031 MITOCHONDRIAL
```

(MITOCHONDRIAL OR MITOCHONDRIALS)

6890 MALATE
 368 MALATES
 7208 MALATE
 (MALATE OR MALATES)

19368 DEHYDROGENASE
 1522 DEHYDROGENASES
 19798 DEHYDROGENASE
 (DEHYDROGENASE OR DEHYDROGENASES)

16 MITOCHONDRIAL MALATE DEHYDROGENASE
 (MITOCHONDRIAL (W) MALATE (W) DEHYDROGENASE)

L1 807 MDH OR (MITOCHONDRIAL MALATE DEHYDROGENASE)

=> s (HIV-1 TAT) or (human deficiency virus TAT)
 30850 HIV
 93 HIVS
 30855 HIV
 (HIV OR HIVS)

1030175 1
 19197 TAT
 406 TATS
 19520 TAT
 (TAT OR TATS)

591 HIV-1 TAT
 (HIV(W) 1 (W) TAT)

207671 HUMAN
 81883 HUMANS
 216869 HUMAN
 (HUMAN OR HUMANS)

28257 DEFICIENCY
 27613 DEFICIENCIES
 49637 DEFICIENCY
 (DEFICIENCY OR DEFICIENCIES)

65233 VIRUS
 46247 VIRUSES
 74697 VIRUS
 (VIRUS OR VIRUSES)

19197 TAT
 406 TATS
 19520 TAT
 (TAT OR TATS)

3 HUMAN DEFICIENCY VIRUS TAT
 (HUMAN (W) DEFICIENCY (W) VIRUS (W) TAT)

L2 594 (HIV-1 TAT) OR (HUMAN DEFICIENCY VIRUS TAT)

=> s 11 and 12
 L3 15 L1 AND L2

=> s 13 not py>2002
 414028 PY>2002
 L4 6 L3 NOT PY>2002

=> d ibib 1-6

L4 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2001057277 PCTFULL ED 20020827
 TITLE (ENGLISH): HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
 USEFUL FOR ANALYSIS OF GENE EXPRESSION IN HUMAN FETAL
 LIVER
 TITLE (FRENCH): SONDES D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
 GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
 DANS LE FOIE FOETAL HUMAIN
 INVENTOR(S): PENN, Sharron, G.;
 HANZEL, David, K.;

PATENT ASSIGNEE(S):
 CHEN, Wensheng;
 RANK, David, R.
 MOLECULAR DYNAMICS, INC.;
 PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.
 Patent

DOCUMENT TYPE:
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001057277	A2	20010809

DESIGNATED STATES
 W:
 AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG
 WO 2001-US669 A 20010130
 US 2000-60/180,312 20000204
 US 2000-60/207,456 20000526
 US 2000-09/608,408 20000630
 US 2000-09/632,366 20000803
 US 2000-60/234,687 20000921
 US 2000-60/236,359 20000927
 GB 2000-0024263.6 20001004

APPLICATION INFO.:
 PRIORITY INFO.:

NUMBER	KIND	DATE
WO 2001057273	A2	20020827

L4 ANSWER 2 OF 6
 ACCESSION NUMBER:
 2001057273
 TITLE (ENGLISH):
 HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
 USEFUL FOR ANALYSIS OF GENE EXPRESSION IN HUMAN ADULT
 LIVER
 SONDES D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
 GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
 DANS LE FOIE ADULTE HUMAIN

TITLE (FRENCH):
 SONDES D'ACIDE NUCLEIQUE A UN SEUL EXON DERIVEES DU
 GENOME HUMAIN UTILES POUR ANALYSER L'EXPRESSION GENIQUE
 DANS LE FOIE ADULTE HUMAIN

INVENTOR(S):
 PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.
 AEOMICA, INC.;
 PENN, Sharron, G.;
 HANZEL, David, K.;
 CHEN, Wensheng;
 RANK, David, R.

PATENT ASSIGNEE(S):
 CHEN, Wensheng;
 RANK, David, R.
 Patent

DOCUMENT TYPE:
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001057273	A2	20010809

DESIGNATED STATES
 W:
 AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG
 WO 2001-US664 A 20010130
 US 2000-60/180,312 20000204
 US 2000-60/207,456 20000526

APPLICATION INFO.:
 PRIORITY INFO.:

US 2000-09/608,408	20000630
US 2000-09/632,366	20000803
US 2000-60/234,687	20000921
US 2000-60/236,359	20000927
GB 2000-0024263.6	20001004

L4 ANSWER 3 OF 6
 ACCESSION NUMBER: PCTFULL COPYRIGHT 2006 Univentio on STN
 2000029421 PCTFULL ED 20020515
 TITLE (ENGLISH): SELECTION SYSTEM FOR GENERATING EFFICIENT PACKAGING
 CELLS FOR LENTIVIRAL VECTORS
 SYSTEME DE SELECTION POUR LA PRODUCTION DE CELLULES
 D'ENCAPSIDATION EFFICACE POUR VECTEURS LENTIVIRaux
 INVENTOR(S): MCGUINNESS, Ryan;
 NALDINI, Luigi
 PATENT ASSIGNEE(S): CELL GENESYS, INC.;
 MCGUINNESS, Ryan;
 NALDINI, Luigi
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 2000029421	A1	20000525
---------------	----	----------

DESIGNATED STATES
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
 DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
 KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
 AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
 GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
 ML MR NE SN TD TG
 APPLICATION INFO.: WO 1999-US24018 A 19991112
 PRIORITY INFO.: US 1998-60/108,169 19981113

L4 ANSWER 4 OF 6
 ACCESSION NUMBER: PCTFULL COPYRIGHT 2006 Univentio on STN
 1999060012 PCTFULL ED 20020515
 TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF
 OLIGONUCLEOTIDES
 COMPOSITIONS ET PROCEDES POUR L'ADMINISTRATION NON
 PARENTERALE D'OLIGONUCLEOTIDES
 INVENTOR(S): TENG, Ching-Leou;
 COOK, Phillip, D.;
 TILLMAN, Lloyd;
 HARDEE, Gregory, E.;
 ECKER, David, J.;
 MANOHARAN, Muthiah
 PATENT ASSIGNEE(S): ISIS PHARMACEUTICALS, INC.;
 TENG, Ching-Leou;
 COOK, Phillip, D.;
 TILLMAN, Lloyd;
 HARDEE, Gregory, E.;
 ECKER, David, J.;
 MANOHARAN, Muthiah
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9960012	A1	19991125
------------	----	----------

DESIGNATED STATES
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
 EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
 KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL

PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
TG

APPLICATION INFO.:
PRIORITY INFO.:

WO 1999-US11394 A 19990520
US 1998-09/082,624 19980521

L4 ANSWER 5 OF 6

ACCESSION NUMBER:

TITLE (ENGLISH):

PCTFULL COPYRIGHT 2006 Univentio on STN

1999011820 PCTFULL ED 20020515

COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND
QUANTITATION OF DELETION SEQUENCE OLIGONUCLEOTIDES IN
SYNTHETIC OLIGONUCLEOTIDE PREPARATIONS

TITLE (FRENCH):

COMPOSITIONS ET PROCEDES D'IDENTIFICATION ET DE
QUANTIFICATION D'OLIGONUCLEOTIDES A SEQUENCE DE
DELETION DANS DES PREPARATIONS D'OLIGONUCLEOTIDES DE
SYNTHESE

INVENTOR(S):

CHEN, Danhua;

SRIVATSA, G., Susan

ISIS PHARMACEUTICALS, INC.;

CHEN, Danhua;

SRIVATSA, G., Susan

English

Patent

LANGUAGE OF PUBL.:

DOCUMENT TYPE:

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9911820 A1 19990311

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

PRIORITY INFO.:

WO 1998-US18084 A 19980901
US 1997-08/923,771 19970902

L4 ANSWER 6 OF 6

ACCESSION NUMBER:

TITLE (ENGLISH):

PCTFULL COPYRIGHT 2006 Univentio on STN

1998027425 PCTFULL ED 20020514

LARGE-SCALE PURIFICATION OF FULL LENGTH
OLIGONUCLEOTIDES BY SOLID-LIQUID AFFINITY EXTRACTION
PURIFICATION A GRANDE ECHELLE D'OLIGONUCLEOTIDES DE
LONGUEUR TOTALE PAR EXTRACTION PAR AFFINITE
SOLIDE-LIQUIDE

INVENTOR(S):

CHEN, Danhua;

SRIVATSA, Githa, Susan;

COLE, Douglas, L.

ISIS PHARMACEUTICALS, INC.;

CHEN, Danhua;

SRIVATSA, Githa, Susan;

COLE, Douglas, L.

English

Patent

PATENT ASSIGNEE(S):

LANGUAGE OF PUBL.:

DOCUMENT TYPE:

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9827425 A1 19980625

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH

GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1997-US23284 A 19971218
PRIORITY INFO.: US 1996-8/769,951 19961219

=> d kwic 2

L4 ANSWER 2 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

=> d kwic 4

L4 ANSWER 4 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . gag 28, 29
HIV AR 177 30
HIV / tat, vpr, rev, 31r 32
env, nef
HIV / pol, env, vir 3 3 3 4
 HIV-1 / tat, rev, env, 3 5 3 6
nef
HIV / gp120 ISIS 5320 37
Hepatitis C virus ISIS 6547 38
- 68

TABLE 6: OLIGONUCLEOTIDES DESIGNED. . .

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, . . .

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, . . .

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.66	10.87

STN INTERNATIONAL LOGOFF AT 13:11:35 ON 29 JUN 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:33:47 ON 29 JUN 2006

=> file pctfull
COST IN U.S. DOLLARS
SINCE FILE ENTRY TOTAL
SESSION
0.21 0.21
FULL ESTIMATED COST

FILE 'PCTFULL' ENTERED AT 13:34:04 ON 29 JUN 2006

COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 27 JUN 2006 <20060627/UP>
MOST RECENT UPDATE WEEK: 200625 <200625/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<
>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
SEE
<http://www.stn-international.de/stndatabases/details/ ipc-reform.html> >>>
>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<
>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,
PLEASE SEE HELP COST <<<
=> s WO200166689/pn
L1 1 WO200166689/PN
(WO2001066689/PN)
=> s l1 and (growth factor)
142211 GROWTH
2617 GROWTHS
142685 GROWTH
(GROWTH OR GROWTHS)
180880 FACTOR
189280 FACTORS
271252 FACTOR
(FACTOR OR FACTORS)
42337 GROWTH FACTOR
(GROWTH(W) FACTOR)
L2 1 L1 AND (GROWTH FACTOR)
=> d kwic
L2 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2006 Univentio on STN
PI WO 2001066689 A2 20010913
DETD 4,10.4 STEM CELL GROWTH FACTOR ACTIVITY
A polypeptide of the present invention may exhibit stem cell
growth factor activity and
be involved in the proliferation, differentiation and survival of
pluripotent and totipotent stem
I 0 cells including primordial germ cells, . . .
It is contemplated that multiple different exogenous growth
factors and/or cytokines may
be administered in combination with the polypeptide of the invention to
achieve the desired
effect, including any of the growth factors listed
herein, other stem cell maintenance factors, and
specifically including stem cell factor (SCF), leukemia inhibitory
factor (LIF), Flt-3 ligand (Flt-
3L), . . . soluble IL-6 receptor fused to IL-6, macrophage
inflammatory protein 1-]Ipha (MIP- I -alpha), G-CSF, GM-CSF,
thrombopoietin (TPO), platelet
factor 4 (PF-4), platelet-derived growth factor
(PDGF), neural growth factors and basic fibroblast
growth factor (bFGF).
mature cells. Techniques
for culturing stem cells are known in the art and administration of

polypeptides of the invention, optionally with other growth factors and/or cytokines, is expected to enhance the survival and proliferation of the stem cell populations. This can be accomplished by direct. . .

In vitro cultures of stem cells can be used to determine if the polypeptide of the invention exhibits stem cell growth factor activity. Stem cells are isolated from any one of various cell 42 sources (including hematopoietic stem cells and embryonic stem cells) and. . . Acad. Sci, U.S.A., 92: 7844-7848 (1995), in the presence of the polypeptide of the invention alone or in combination with other growth

 factors or cytokines. The ability of the polypeptide of the invention to induce stem cells proliferation is determined by colony formation on. . .

 invention may be combined with other agents beneficial to the treatment of the disease or disorder in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF-a and TGF-P), insulin-like growth factor (IGF), as well as cytokines described herein.

 with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-a and TGF-P), and insulin-like growth factor (IGF).

 matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor 1), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, . . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.45	5.66

STN INTERNATIONAL LOGOFF AT 13:36:21 ON 29 JUN 2006